Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Awaiting nod from Drug Controller General of India for phase 3 trials
Subscribe to our email newsletter
The US Food and Drug Administration (USFDA) has approved Indus Biotech to conduct clinical trails for its molecule, IND02, reported The Economic Times.
The newly developed molecule is intended for the treatment of AIDS and soon the company is going to begin phase 1 trials in the US.
The company is awaiting a nod from Drug Controller General of India (DCGI) for its phase 3 trials.
Indus claims that an HIV patient will be able to stop the advancement of the disease after an effective usage of the molecule.
Sanjay Bhaskaran, managing director at Indus, said: “We have also discovered that the same molecule can be used to cure H1N1 and have filed an application with the USFDA and the DCGI for that as well. Once the approval for the H1N1 indication is cleared we will start trials for that.”
Rajan Srinivasan, executive director at Indus, said: “The idea of developing drugs based on plant extracts is so that the toxicology is low. These are plants that are part of the food raw chain yet do not fall under the ayurvedic or alternative medicine category,” quoted the newspaper.